Simcere Zaiming is a pharmaceutical company specializing in oncology, and a subsidiary of Simcere Pharmaceutical Group Limited, that focuses on the R&D, production and commercialization of innovative cancer therapeutics. The company was formed in 2023 and is committed to solving unmet clinical needs for cancer patients in China and around the world by developing breakthrough treatments. Simcere Zaiming has an innovative R&D pipeline with differentiated clinical value, among which 15 assets are currently in clinical trials. In addition to the company’s R&D portfolio, Simcere Zaiming is marketing three innovative drugs, COSELA®, Endostar®, and Envafolimab®. By collaborating with partners globally, Simcere Zaiming strives to bring potentially new innovative therapeutics to cancer patients worldwide.
Company Details
- Employees
- 35
- Founded
- -
- Address
- 玄武大道, 699-18号 23号楼,china
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- HQ
- 南京, 江苏
Simcere Zaiming Questions
Simcere Zaiming's LinkedIn profile is https://cn.linkedin.com/company/simcere-zaiming
Simcere Zaiming has
35 employees.
View email and phone details for 35
employees at Simcere Zaiming.
Simcere Zaiming's industry is
Pharmaceutical Manufacturing
Simcere Zaiming's top competitors are
Phio Pharmaceuticals Corp.,
Kardigan,
Tune Therapeutics,
Normunity,
Hildred Capital,
Simnova Biotherapeutics,
Salarius Pharmaceuticals,
Timberlyne Therapeutics,
Simcere Pharmaceutical Group,
Scorpion Therapeutics.
Simcere Zaiming's categories are Pharmaceutical Manufacturing
Simcere Zaiming's founding year is 2023
